ARTICLE | Clinical News
Parsabiv regulatory update
November 15, 2016 9:24 PM UTC
The European Commission approved an MAA from Amgen for Parsabiv etelcalcetide to treat secondary hyperparathyroidism in adults with chronic kidney disease (CKD) on hemodialysis. In August, FDA issued ...